Claims for Patent: 8,987,292

Summary for Patent: 8,987,292

Title:	Rifaximin anti-rectal dysfunction preparation
Abstract:	The present invention relates to compositions and methods for treating rectal disorders.
Inventor(s):	Safdi; Alan (Cincinnati, OH), Taylor; David (Chapel Hill, NC)
Assignee:	Salix Pharmaceuticals, Ltd. (Raleigh, NC)
Application Number:	12/224,774
Patent Claims:	1. A pharmaceutical preparation comprising nitroglycerin and rifaximin. 2. The pharmaceutical preparation of claim 1, wherein the nitroglycerin comprises from between about 0.1% to about 10% of the preparation by weight. 3. The pharmaceutical preparation of claim 1, wherein the nitroglycerin comprises from between about 10% to about 50% of the preparation by weight. 4. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 10% to about 99% of the preparation by weight. 5. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 25 mg to about 800 mg. 6. The pharmaceutical preparation of claim 1, wherein the rifaximin comprises from between about 100 mg to about 200 mg. 7. The pharmaceutical preparation of claim 1, further comprising at least one additional therapeutic agents. 8. The pharmaceutical preparation of claim 7, wherein the at least one additional therapeutic agents is selected from the group consisting of: anti-inflammatory agents, botox, antibiotics, antiviral compounds, anti-neoplastic compounds, anaesthetics, or anti-fungal agents. 9. A pharmaceutical preparation comprising from between about 100 to about 200 mg rifaximin and from between about 0.1% and about 2% hydrocortisone. 10. The pharmaceutical preparation of claim 9, further comprising from between about 0.01% to about 1% nitroglycerine. 11. The pharmaceutical preparation of claim 1, wherein the preparation comprises an enema, a foam, an ointment, a paste, or a suppository. 12. A method of treating a subject suffering from an anal disorder comprising administering an effective amount of an nitroglycerin and rifaximin proximal or to an affected area of the subject. 13. The method of claim 12, wherein the affected area comprises one or more of the external anus or distal anal canal of the subject. 14. The method of claim 12, wherein the anal disorder selected from one or more of anal fissure, anal ulcer, acute hemorrhoidal disease, Crohn's disease, irritable bowel syndrome, hemorrhoidal disease, irritable bowel syndrome, inflammatory bowel disease, travelers' diarrhea, large intestinal anal disease, chronic pancreatitis, pancreatic insufficiency or post-surgical disease. 15. The method of claim 12, wherein the administering is topical. 16. The method of claim 12, wherein the administering is via a suppository. 17. The method of claim 12, wherein the preparation is applied proximal or to the affected area of the external anus or distal anal canal of the subject. 18. The method of claim 12, wherein the nitroglycerin comprises from between about 0.01% to 10% by weight of the preparation. 19. The method of claim 12, wherein the rifaximin comprises from between about 0.01% to 10% by weight of the preparation. 20. The method of claim 12, wherein the preparation further comprises a carrier. 21. The method of claim 20, wherein the carrier is selected from one or more of white petrolatum, mineral oil, lanolin, distilled water, acetone, and cocoa butter. 22. The method of claim 12, further comprising a corticosteroid. 23. The method of claim 12, further comprising a local anesthetic. 24. The method of claim 12, wherein the composition is formulated as an ointment, a cream, a gel, or a lotion. 25. The method of claim 12, wherein the composition is formulated as a liquid or semisolid. 26. The method of claim 12, wherein the composition is formulated as a suppository. 27. A method of assessing the efficacy of an anal disorder treatment in a subject, monitoring the progress of a subject being treated for an anal disorder, or selecting a subject for treatment of an anal disorder, comprising: determining a pre-treatment level of anal disease; administering a therapeutically effective amount of preparation according to claim 1 to the subject; and determining a post-treatment level of anal disease after an initial period of treatment with the preparation. 28. The method of claim 27, wherein the modulation of the level of anal disease indicates efficacy of the treatment. 29. The method of claim 27, wherein a decrease in anal disease indicates that the treatment is efficacious.

Details for Patent 8,987,292

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Allergan, Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	12/09/1991		2026-03-09
Allergan, Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	12/09/1991		2026-03-09